SynthesisAdvances in therapy2024

Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer.

Maria De Santis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.